B. Sleckman

A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.

M. Vannier, M. Edelman, H. Lenz, 2012 .

Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

M. Vannier, H. Lenz, W. Stadler, 2013 .

Epstein-Barr Virus in Hodgkin’s Disease: Correlation of Risk Factors and Disease Characteristics with Molecular Evidence of Viral

É., G., A. Perez-Atayde, 2005 .

Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection.

G. Pinkus, A. Perez-Atayde, I. Thior, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

K. Gelmon, H. Rugo, A. DeMichele, 2019, The breast journal.

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial.

R. Govindan, M. Ranson, N. Rizvi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study

R. Govindan, M. Ranson, N. Rizvi, 2005 .

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

R. Salgia, H. Lenz, F. D. de Sauvage, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

Sonali M. Smith, Krishna Rao, A. Rapoport, 2020, Haematologica.

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

R. Govindan, M. Ranson, N. Rizvi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

S. Loi, H. Rugo, R. Finn, 2022, Breast.

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

E. Vokes, W. Stadler, D. Taber, 2012, Investigational New Drugs.

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study

E. Vokes, T. Seiwert, W. Stadler, 2020, Cancer.

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Sonali M. Smith, Krishna Rao, A. Rapoport, 2016 .

Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials

H. Rugo, C. Isaacs, Xin Huang, 2022, Cancer Research.